[go: up one dir, main page]

MX2015005363A - Variantes de albumina. - Google Patents

Variantes de albumina.

Info

Publication number
MX2015005363A
MX2015005363A MX2015005363A MX2015005363A MX2015005363A MX 2015005363 A MX2015005363 A MX 2015005363A MX 2015005363 A MX2015005363 A MX 2015005363A MX 2015005363 A MX2015005363 A MX 2015005363A MX 2015005363 A MX2015005363 A MX 2015005363A
Authority
MX
Mexico
Prior art keywords
variants
albumin variants
relates
present
parent albumin
Prior art date
Application number
MX2015005363A
Other languages
English (en)
Inventor
Jan Terje Andersen
Jason Cameron
Andrew Plumridge
Karen Delahay
Jens Erik Nielsen
Original Assignee
Novozymes Biopharma Dk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes Biopharma Dk As filed Critical Novozymes Biopharma Dk As
Publication of MX2015005363A publication Critical patent/MX2015005363A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)

Abstract

La presente invención se relaciona a variantes de una albúmina precursora, las variantes que tienen vida media de plasma alterada comparada con la albúmina precursora. La presente invención también se relaciona a polinucleótidos que codifican las variantes; constructos de ácidos nucleótidos, vectores, y células huésped que comprenden los polinucleótidos; y métodos de usar las variantes.
MX2015005363A 2012-11-08 2013-11-08 Variantes de albumina. MX2015005363A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12191856 2012-11-08
PCT/EP2013/073426 WO2014072481A1 (en) 2012-11-08 2013-11-08 Albumin variants

Publications (1)

Publication Number Publication Date
MX2015005363A true MX2015005363A (es) 2015-11-06

Family

ID=47137625

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005363A MX2015005363A (es) 2012-11-08 2013-11-08 Variantes de albumina.

Country Status (13)

Country Link
US (3) US20140128326A1 (es)
EP (1) EP2917233A1 (es)
JP (2) JP6487328B2 (es)
KR (1) KR20150082422A (es)
CN (1) CN105452290A (es)
AU (2) AU2013343503B2 (es)
BR (1) BR112015010318A2 (es)
CA (1) CA2890766A1 (es)
GB (1) GB2512156A (es)
IL (1) IL238185B (es)
MX (1) MX2015005363A (es)
RU (1) RU2670063C2 (es)
WO (1) WO2014072481A1 (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2630253T3 (es) 2009-02-11 2017-08-18 Albumedix A/S Variantes de albúmina y conjugados
US8748380B2 (en) * 2009-10-30 2014-06-10 Novozymes Biopharma Dk A/S Albumin variants
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN104531812A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
BR112013031943B1 (pt) 2011-06-13 2021-10-13 Csl Limited Composição que compreende proteínas e anticorpos contra g-csfr
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
BR112014007852B1 (pt) 2011-10-03 2021-11-03 Moderna Therapeutics, Inc Polinucleotídeo isolado modificado e composição farmacêutica
AU2012323316B2 (en) 2011-10-11 2017-08-10 Viela Bio, Inc. CD40L-specific Tn3-derived scaffolds and methods of use thereof
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
PL2791160T3 (pl) 2011-12-16 2022-06-20 Modernatx, Inc. Kompozycje zmodyfikowanego mrna
ES2664328T3 (es) 2012-03-16 2018-04-19 Albumedix A/S Variantes de albúmina
HK1206779A1 (en) 2012-04-02 2016-01-15 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
BR112015010318A2 (pt) 2012-11-08 2017-08-22 Albumedix As Variantes de albumina
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
US9926570B2 (en) * 2013-03-06 2018-03-27 Glaxosmithkline Llc Host cells and methods of use
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
TW201609812A (zh) 2014-07-31 2016-03-16 安美基研究（慕尼黑）公司 最佳化之跨物種特異性雙特異性單鏈抗體構築體
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
CA2977675A1 (en) * 2015-03-12 2016-09-15 Medimmune, Llc Method of purifying albumin-fusion proteins
CA2982682A1 (en) 2015-04-17 2016-10-20 Amgen Research (Munich) Gmbh Bispecific antibody constructs for cdh3 and cd3
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
US10633428B2 (en) 2015-08-20 2020-04-28 Albumedix Ltd Albumin variants and conjugates
CA3005953A1 (en) 2015-12-22 2017-06-29 Albumedix Ltd Improved protein expression strains
JP7146637B2 (ja) 2015-12-22 2022-10-04 アルブミディクス リミティド 改善されたタンパク質発現株
CA3010720A1 (en) 2016-01-07 2017-07-13 Csl Behring Recombinant Facility Ag Mutated truncated von willebrand factor
MA43959A (fr) 2016-02-03 2018-12-12 Amgen Res Munich Gmbh Constructions d'anticorps impliquant des cellules t bispécifiques psma et cd3
DK3423577T3 (da) 2016-03-02 2024-07-08 Novozymes As Cellobiohydrolasevarianter og polynukleotider til kodning deraf
WO2017165760A1 (en) 2016-03-24 2017-09-28 Novozymes A/S Cellobiohydrolase variants and polynucleotides encoding same
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
US11110122B2 (en) * 2016-06-03 2021-09-07 New York University Methods and reagents for modulating macrophage phenotype
WO2018082758A1 (en) 2016-11-04 2018-05-11 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
EP3541954A1 (en) 2016-11-21 2019-09-25 Novozymes A/S Yeast cell extract assisted construction of dna molecules
US11655306B2 (en) * 2017-04-05 2023-05-23 Korea Research Institute Of Bioscience And Biotechnology NK cell-activating fusion protein, NK cell, and pharmaceutical composition including same
JP7282693B2 (ja) 2017-06-20 2023-05-29 アルブミディクス リミティド 改良されたタンパク質発現株
JP2020530436A (ja) 2017-06-22 2020-10-22 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト トランケート型ｖｗｆによるｆｖｉｉｉの免疫原性の調節
SI3661954T1 (sl) 2017-08-03 2022-05-31 Amgen Inc. Muteini interlevkina-21 in postopki zdravljenja
ES2985118T3 (es) 2017-09-08 2024-11-04 Amgen Inc Inhibidores de KRAS G12C y métodos de uso de los mismos
CN109553684A (zh) * 2017-09-25 2019-04-02 中国科学院过程工程研究所 一种纳米载体蛋白及其制备方法和应用
DK3717011T5 (da) 2017-11-29 2024-08-26 Csl Ltd Fremgangsmåde til behandling eller forebyggelse af iskæmi-reperfusionsskade
UY38049A (es) 2018-01-12 2019-07-31 Amgen Inc Anti-pd-1 anticuerpos y métodos de tratamiento
US12281160B2 (en) 2018-03-23 2025-04-22 Csl Limited Method of treating asthma
JP2021524846A (ja) 2018-05-16 2021-09-16 シーエスエル、リミテッド 可溶性補体受容体１型変異体及びそれらの使用
MA53325A (fr) 2018-07-30 2021-06-09 Amgen Inc Administration prolongée d'une construction d'anticorps bispécifique se liant à cd33 et cd3
TWI830761B (zh) 2018-08-03 2024-02-01 德商安美基研究（慕尼黑）公司 針對cldn18.2和cd3之抗體構建體
WO2020049151A1 (en) 2018-09-06 2020-03-12 Bavarian Nordic A/S Storage improved poxvirus compositions
US12465640B2 (en) 2019-02-25 2025-11-11 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ECM-affinity peptides linked to anti-inflammatory agents
JP7671739B2 (ja) 2019-09-06 2025-05-02 ノバルティス アーゲー 治療用融合タンパク質
DK3819007T3 (da) 2019-11-11 2024-09-30 Amgen Res Munich Gmbh Doseringsplan for anti-bcma-midler
EP4069200A1 (en) 2019-12-04 2022-10-12 Albumedix Ltd Methods and compositions produced thereby
US20230093169A1 (en) 2020-01-22 2023-03-23 Amgen Research (Munch) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
EP4118113A1 (en) 2020-03-12 2023-01-18 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
IL296250A (en) 2020-03-12 2022-11-01 Bavarian Nordic As Compositions improving poxvirus stability
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer
US12312412B2 (en) 2020-05-19 2025-05-27 Amgen Inc. MAGEB2 binding constructs
MX2022014902A (es) 2020-05-29 2023-01-04 Amgen Inc Administracion mitigadora de efectos adversos de un constructo biespecifico que se une a cd33 y cd3.
WO2022060901A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
AU2021374036A1 (en) 2020-11-06 2023-06-08 Amgen Inc. Polypeptide constructs selectively binding to cldn6 and cd3
KR20230104229A (ko) 2020-11-06 2023-07-07 암젠 인크 Cd3에 결합하는 폴리펩티드 구축물
EP4240407A1 (en) 2020-11-06 2023-09-13 Amgen Inc. Antigen binding domain with reduced clipping rate
WO2022103781A1 (en) 2020-11-10 2022-05-19 Amgen Inc. Methods for administering a bcma x cd3 binding molecule
CN113717873B (zh) * 2021-09-27 2023-04-14 四川大学 一种多重耐受性酿酒酵母菌株及其构建方法和应用
CN113912730B (zh) * 2021-12-14 2022-03-04 北京科诺信诚科技有限公司 缓释的抗FcRn抗体或抗原结合片段及其应用
EP4598958A1 (en) 2022-10-05 2025-08-13 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
WO2024089258A1 (en) 2022-10-28 2024-05-02 Aarhus Universitet Albumin conjugated to cpg oligodeoxynucleotides as super-boosters of immune response
KR20250151445A (ko) 2023-02-17 2025-10-21 아블린쓰 엔.브이. 신생아 fc 수용체에 결합하는 폴리펩티드
WO2024200573A1 (en) 2023-03-27 2024-10-03 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use
EP4442251A1 (en) 2023-04-05 2024-10-09 Albumedix Ltd Formulations and uses thereof
WO2025007195A1 (en) 2023-07-05 2025-01-09 CSL Innovation Pty Ltd Methods of treating or preventing a complication of sickle cell disease
WO2025012118A2 (en) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
WO2025158071A1 (en) 2024-01-26 2025-07-31 Sartorius Albumedix Limited Retroviral preparations containing albumin for enhancing transduction efficiency, uses thereof for cell transduction
US20250313641A1 (en) 2024-04-09 2025-10-09 Amgen Inc. Agonistic anti-il-2rbg heavy-chain antibodies
EP4653010A1 (en) 2024-05-14 2025-11-26 35Pharma Inc. Activin receptor type iib traps for use in improving body composition

Family Cites Families (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625041A (en) 1990-09-12 1997-04-29 Delta Biotechnology Limited Purification of proteins
GB9019919D0 (en) 1990-09-12 1990-10-24 Delta Biotechnology Ltd Purification of proteins
US2714586A (en) 1951-06-25 1955-08-02 Phillips Petroleum Co Washing urea and thiourea containing adducts
JPS4983148A (es) 1972-12-16 1974-08-09
US4302386A (en) 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
JPS60169498A (ja) 1984-02-10 1985-09-02 Kyowa Hakko Kogyo Co Ltd 成人ｔ細胞白血病ウイルス抗原ペプチド誘導体
MX9203440A (es) 1985-04-12 1992-07-01 Genetics Inst Proteinas procoagulantes novedosas.
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
IE63424B1 (en) 1987-04-09 1995-04-19 Delta Biotechnology Ltd Yeast vector
DE3854249T2 (de) 1987-08-28 1996-02-29 Novonordisk As Rekombinante Humicola-Lipase und Verfahren zur Herstellung von rekombinanten Humicola-Lipasen.
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
IL88326A (en) 1987-11-18 1993-03-15 Gist Brocades Nv Purification of serum albumin
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8909916D0 (en) 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8927722D0 (en) 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
DE4000939A1 (de) 1990-01-15 1991-07-18 Brem Gottfried Prof Dr Dr Verfahren zur antikoerpergewinnung
JP3230091B2 (ja) 1990-06-25 2001-11-19 ウェルファイド株式会社 ヒト血清アルブミンの着色抑制方法
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
CA2058820C (en) 1991-04-25 2003-07-15 Kotikanyad Sreekrishna Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DE4226971C2 (de) 1992-08-14 1997-01-16 Widmar Prof Dr Tanner Modifizierte Pilzzellen und Verfahren zur Herstellung rekombinanter Produkte
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
WO1995003402A1 (en) 1993-07-22 1995-02-02 Merck & Co., Inc. EXPRESSION OF HUMAN INTERLEUKIN-1β IN A TRANSGENIC ANIMAL
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US6811773B1 (en) 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB9404270D0 (en) 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5716808A (en) 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6509313B1 (en) 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US5854039A (en) 1996-07-17 1998-12-29 Zymogenetics, Inc. Transformation of pichia methanolica
US6274305B1 (en) 1996-12-19 2001-08-14 Tufts University Inhibiting proliferation of cancer cells
US6605699B1 (en) 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
US7053190B2 (en) 1997-03-07 2006-05-30 Human Genome Sciences, Inc. Secreted protein HRGDF73
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
US6506569B1 (en) 1997-05-30 2003-01-14 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR10
US5948609A (en) 1997-12-03 1999-09-07 Carter; Daniel C. Oxygen-transporting albumin-based blood replacement composition and blood volume expander
WO2000008207A1 (en) 1998-08-06 2000-02-17 Syntron Bioresearch, Inc. Uric acid assay device with stabilized uricase reagent composition
CA2356542A1 (en) 1998-12-23 2000-07-06 Human Genome Sciences, Inc. Peptidoglycan recognition proteins
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
WO2001077137A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
ES2334106T3 (es) 1999-05-17 2010-03-05 Conjuchem Biotechnologies Inc. Inhibidores peptidos de fusion de larga vida contra infecciones virales.
CA2371912C (en) 1999-05-21 2010-02-16 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
WO2001070968A2 (en) 2000-03-22 2001-09-27 Octagene Gmbh Production of recombinant blood clotting factors in human cell lines
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
US6943240B2 (en) 2000-09-15 2005-09-13 Coley Pharmaceuticals Gmbh Nucleic acids for high throughput screening of CpG-based immuno-agonist/antagonist
AU2002245204A1 (en) 2000-10-25 2002-07-24 Genzyme Corporation Methods for treating blood coagulation disorders
WO2002043658A2 (en) 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders
BR0116024A (pt) 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
DK1385864T3 (da) 2001-04-13 2010-08-16 Human Genome Sciences Inc Anti-VEGF-2-antistoffer
AUPR446701A0 (en) 2001-04-18 2001-05-17 Gene Stream Pty Ltd Transgenic mammals for pharmacological and toxicological studies
EP1406917A4 (en) 2001-06-15 2007-11-14 New Century Pharmaceuticals HUMAN ANALYTICAL MODELS FOR THE EVALUATION OF MEDICINAL PRODUCTS AND FOR TOXICOLOGICAL AND IMMUNOGENIC EXAMINATIONS
EP1421187B1 (en) 2001-07-27 2007-10-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Systems for in vivo site-directed mutagenesis using oligonucleotides
CN1405182A (zh) 2001-08-10 2003-03-26 中国人民解放军军事医学科学院生物工程研究所 血清白蛋白与粒细胞集落刺激因子的融合蛋白
EP2277889B1 (en) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
US20080167238A1 (en) 2001-12-21 2008-07-10 Human Genome Sciences, Inc. Albumin Fusion Proteins
CA2484556A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
KR20040095217A (ko) 2002-02-07 2004-11-12 델타 바이오테크놀로지 리미티드 알부민-융합 항-혈관신생 펩타이드
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
US6995933B1 (en) 2002-04-30 2006-02-07 Western Digital Technologies, Inc. Disk drive for optimizing write current settings relative to drive operating characteristics and ambient temperature readings
WO2003102136A2 (en) 2002-05-30 2003-12-11 Human Genome Sciences, Inc. Antibodies that specifically bind to neurokinin b
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
GB0217347D0 (en) 2002-07-26 2002-09-04 Univ Edinburgh Novel albumins
EP1572955A2 (en) 2002-08-02 2005-09-14 Human Genome Sciences, Inc. Antibodies against c3a receptor
US7749713B2 (en) 2002-11-19 2010-07-06 Hasan Kulaksiz Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
ATE411819T1 (de) 2003-02-17 2008-11-15 Upperton Ltd Konjugate für medizinische abbildungen umfassend träger, targeting-anteile und kontrastmittel
GB0305989D0 (en) 2003-03-15 2003-04-23 Delta Biotechnology Ltd Agent
WO2004082640A2 (en) 2003-03-19 2004-09-30 New Century Pharmaceuticals, Inc. Human serum albumin conjugates with therapeutic compounds
CA2522680A1 (en) 2003-04-15 2004-10-28 Xenon Pharmaceuticals Inc. Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
US20050079546A1 (en) 2003-05-01 2005-04-14 Dasa Lipovsek Serum albumin scaffold-based proteins and uses thereof
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
US20080308744A1 (en) 2003-11-18 2008-12-18 Beth Israel Deaconess Medical Center Serum Albumin Conjugated to Fluorescent Substances for Imaging
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
WO2006067511A1 (en) 2004-12-23 2006-06-29 Novozymes Delta Limited Gene expression technique
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
JP4649954B2 (ja) 2003-12-26 2011-03-16 ニプロ株式会社 抗菌作用が増強されたアルブミン
US7166577B2 (en) 2003-12-26 2007-01-23 Nipro Corporation Albumin having enhanced antimicrobial activity
KR100671005B1 (ko) 2004-01-15 2007-01-18 고려대학교 산학협력단 Ｐａｈ 노출 여부 진단용 바이오 마커 단백질
RU2369404C2 (ru) * 2004-02-09 2009-10-10 Хьюман Дженом Сайенсиз, Инк. Слитые белки альбумина
CA2554089C (en) 2004-02-09 2013-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
JP4492156B2 (ja) 2004-03-03 2010-06-30 ニプロ株式会社 血清アルブミンドメインを含む蛋白質
US20060018859A1 (en) 2004-07-16 2006-01-26 Carter Daniel C Modified human serum albumin with reduced or eliminated affinity to chemical or biological contaminants at Cys 34
US20060051859A1 (en) 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
US20090280534A1 (en) 2004-12-22 2009-11-12 Novozymes A/S Recombinant Production of Serum Albumin
WO2006073195A1 (ja) 2005-01-07 2006-07-13 Biomarker Science Co., Ltd 糖尿病の予知・診断方法および糖尿病予知・診断用キット
US20060178301A1 (en) 2005-02-04 2006-08-10 Mathias Jurs Albumin-fused ciliary neurotrophic factor
CA2606378A1 (en) 2005-04-29 2006-11-09 The Jackson Laboratory Fcrn antibodies and uses thereof
GB0512707D0 (en) 2005-06-22 2005-07-27 Delta Biotechnology Ltd Gene expression technique
EP1924596A4 (en) 2005-08-12 2009-07-29 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
CA2562249A1 (en) 2005-10-20 2007-04-20 University Of Ottawa Heart Institute Anf analogue
JP2009520469A (ja) 2005-12-22 2009-05-28 コンジュクヘム ビオテクフノロギエス インコーポレイテッド アルブミンと治療薬との前もって形成された抱合体の産生のための方法
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2007112940A2 (en) 2006-03-31 2007-10-11 Ablynx N.V. Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
WO2007146038A2 (en) 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
ES2910207T3 (es) 2006-06-14 2022-05-11 Csl Behring Gmbh Proteínas de fusión escindibles proteolíticamente que comprenden un factor de coagulación de la sangre
KR101507021B1 (ko) 2006-07-13 2015-03-30 업퍼톤 리미티드 단백질성 물질의 입자를 제조하기 위한 방법
JP4983148B2 (ja) 2006-08-18 2012-07-25 ニプロ株式会社 糖鎖含有アルブミン、その製造方法およびその用途
CA2663083A1 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
US20100129846A1 (en) 2006-12-07 2010-05-27 Power3 Medical Products, Inc. Isoform specificities of blood serum proteins and their use as differentially expressed protein biomarkers for diagnosis of breast cancer
CA2695830A1 (en) 2007-08-08 2009-02-12 Novozymes Biopharma Dk A/S Transferrin variants and conjugates
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
CA2611540C (en) 2007-11-09 2017-05-30 Nipro Corporation Sugar chain-containing albumin as a drug carrier to the liver
EP2245064B1 (en) 2007-12-21 2014-07-23 Medimmune Limited BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ralpha)
PL2288715T3 (pl) 2008-04-11 2015-03-31 Merrimack Pharmaceuticals Inc Łączniki będące albuminą surowicy ludzkiej i ich koniugaty
US20110112040A1 (en) 2008-04-28 2011-05-12 President And Fellows Of Harvard College Supercharged proteins for cell penetration
EP2310526A4 (en) 2008-07-18 2011-11-02 Oragenics Inc COMPOSITIONS FOR THE DETECTION AND TREATMENT OF COLORECTAL CARCINOMAS
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
CA2893696C (en) 2008-12-05 2018-09-04 Abraxis Bioscience, Llc Albumin binding peptide-mediated disease targeting
CN102307905B (zh) 2008-12-10 2015-11-25 斯克利普斯研究院 利用化学反应性非天然氨基酸产生载体-肽偶联物
ES2630253T3 (es) 2009-02-11 2017-08-18 Albumedix A/S Variantes de albúmina y conjugados
CA2757897A1 (en) 2009-04-08 2010-10-14 Anna M. Wu Human protein scaffold with controlled serum pharmacokinetics
JP2012525146A (ja) 2009-04-28 2012-10-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ 細胞透過のための過剰に荷電されたタンパク質
US8232067B2 (en) 2009-05-29 2012-07-31 Brigham & Women's Hospital, Inc. Disrupting FCRN-albumin interactions
US20120134984A1 (en) 2009-06-01 2012-05-31 Olga Lubman Molecules with extended half-lives and uses thereof
KR101286721B1 (ko) 2009-06-05 2013-07-16 한국과학기술연구원 폴리-시스테인 펩티드 융합 재조합 알부민 및 이의 제조방법
TWI557224B (zh) 2009-07-20 2016-11-11 國立成功大學 具αｖβ３整合蛋白選擇性且與人類血清白蛋白（ＨＳＡ）變體結合之多肽及其於醫藥上之用途
EP2456787A4 (en) 2009-07-24 2013-01-30 Univ Leland Stanford Junior CYTOKIN COMPOSITIONS AND METHOD FOR THEIR USE
EP2464974A1 (en) 2009-08-10 2012-06-20 UCL Business PLC Functionalisation of solid substrates
UY32920A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
BR112012008444A2 (pt) 2009-10-10 2019-09-24 Eleven Biotherapeutics Inc proteína isolada, composição farmacêutica, métodos para modular uma resposta imune ou inflamatória em um sujeito, para tratar um distúrbio mediado po ir-17 em um sujeito e para preparar uma proteína recombinante, ácido nucleico isolado, e, célula hospedeira recombinante
US8748380B2 (en) 2009-10-30 2014-06-10 Novozymes Biopharma Dk A/S Albumin variants
US9044436B2 (en) 2009-12-23 2015-06-02 National Cheng Kung University Compositions and methods for the treatment of angiogenesis-related eye diseases
CN101875693B (zh) 2010-01-22 2012-07-18 成都正能生物技术有限责任公司 具备抗血管生成活性的白蛋白变异体及其制备方法
CN104610454A (zh) 2010-02-16 2015-05-13 米迪缪尼有限公司 Hsa相关组合物及使用方法
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
US8691771B2 (en) 2010-05-21 2014-04-08 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins for tissue repair
WO2011161127A1 (en) 2010-06-21 2011-12-29 Medimmune, Llc Protease variants of human neprilysin
US9012609B2 (en) 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants
WO2012059486A1 (en) * 2010-11-01 2012-05-10 Novozymes Biopharma Dk A/S Albumin variants
JP2014510518A (ja) * 2011-02-15 2014-05-01 メディミューン，エルエルシー Ｈｓａ関連組成物および使用方法
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
JP5641536B2 (ja) * 2011-03-15 2014-12-17 日本パーカライジング株式会社 固定砥粒ソーワイヤー用電着液
CN104011072B (zh) 2011-05-05 2018-10-12 阿尔布梅迪克斯医疗有限公司 白蛋白变体
WO2013010840A2 (en) 2011-07-18 2013-01-24 Arts Biologics A/S Long acting biologically active luteinizing hormone (lh) compound
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
ES2664328T3 (es) * 2012-03-16 2018-04-19 Albumedix A/S Variantes de albúmina
WO2014005596A1 (en) 2012-07-03 2014-01-09 Aarhus Universitet Modified payload molecules and their interactions and uses
US8757798B2 (en) 2012-08-31 2014-06-24 Cody Air LLC Eyewear frame
BR112015010318A2 (pt) 2012-11-08 2017-08-22 Albumedix As Variantes de albumina
KR20150118123A (ko) 2013-02-16 2015-10-21 노보자임스 바이오파마 디케이 에이/에스 약동학적 동물 모델
US20160052993A1 (en) 2013-05-03 2016-02-25 Eleven Biotherapeutics, Inc. Albumin variants binding to fcrn
WO2015036579A1 (en) 2013-09-13 2015-03-19 Novozymes Biopharma Dk A/S Albumin variants
JP6306700B2 (ja) 2013-11-01 2018-04-04 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ アルブミン改変体及びその使用
US10633428B2 (en) 2015-08-20 2020-04-28 Albumedix Ltd Albumin variants and conjugates

Also Published As

Publication number Publication date
GB201319754D0 (en) 2013-12-25
AU2018201136A1 (en) 2018-03-08
WO2014072481A1 (en) 2014-05-15
CA2890766A1 (en) 2014-05-15
GB2512156A (en) 2014-09-24
US20200102367A1 (en) 2020-04-02
US10501524B2 (en) 2019-12-10
US20140128326A1 (en) 2014-05-08
KR20150082422A (ko) 2015-07-15
JP6487328B2 (ja) 2019-03-20
CN105452290A (zh) 2016-03-30
IL238185A0 (en) 2015-05-31
US20150210752A1 (en) 2015-07-30
BR112015010318A2 (pt) 2017-08-22
RU2670063C2 (ru) 2018-10-17
EP2917233A1 (en) 2015-09-16
US10934341B2 (en) 2021-03-02
IL238185B (en) 2019-09-26
AU2013343503B2 (en) 2017-12-14
AU2013343503A1 (en) 2015-04-30
JP2015535300A (ja) 2015-12-10
RU2015121693A (ru) 2016-12-27
JP2019048821A (ja) 2019-03-28

Similar Documents

Publication Publication Date Title
MX2015005363A (es) Variantes de albumina.
MX2014010278A (es) Variantes de albumina.
MX353621B (es) Variantes de alfa-amilasa.
IN2014CN00597A (es)
MX351762B (es) Variantes de glucoamilasas y polinucleotidos que las codifican.
MX351154B (es) Variantes de glucoamilasas y polinucleotidos que las codifican.
EP4477734A3 (en) Protease variants and polynucleotides encoding same
MX337984B (es) Variantes de alfa amilasa y polinucleotidos que codifican la misma.
MX355356B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX2014004539A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
WO2014177546A3 (en) Glucoamylase variants and polynucleotides encoding same
MX352023B (es) Variantes de alfa-amilasa con estabilidad mejorada.
MX351916B (es) Polipeptidos que tienen actividad de lisozima y polinucleotdos que los codifican.
MX2013007997A (es) Polipeptidos que tienen actividad de incremento celulolitico y polinucleotidos que codifican para los mismos.
WO2012044915A3 (en) Beta-glucosidase variants and polynucleotides encoding same
MX2015000312A (es) Polipeptidos que tienen actividad lipasa y polinucleotidos que los codifican.
MX2021013104A (es) Variantes de lipasa y polinucleotidos que las codifican.
WO2014195356A3 (en) Alpha-amylase variants and polynucleotides encoding same
WO2011109524A3 (en) Xylanase variants and polynucleotides encoding same
MX363261B (es) Polipéptidos que tienen actividad de la fosfolipasa a y polinucleótidos que los codifican.
WO2013096603A3 (en) Cellobiohydrolase variants and polynucleotides encoding same
WO2014177541A3 (en) Glucoamylase variants and polynucleotides encoding same
MX2014001594A (es) Polipeptidos que tienen actividad de celulasa y polinucleotidos que los codifican.
MX349517B (es) Polipeptidos que tienen actividad de proteasa y polinucleotidos que codifican los mismos.
IN2014CN03187A (es)